Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors

Bioorg Med Chem Lett. 2009 Feb 1;19(3):817-20. doi: 10.1016/j.bmcl.2008.12.011. Epub 2008 Dec 7.

Abstract

Two new series of potent and selective dual EGFR/ErbB-2 kinase inhibitors derived from novel thienopyrimidine cores have been identified. Isomeric thienopyrimidine cores were evaluated as isosteres for a 4-anilinoquinazoline core and several analogs containing the thieno[3,2-d]pyrimidine core showed anti-proliferative activity with IC(50) values less than 1 microM against human tumor cells in vitro.

MeSH terms

  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / pharmacology*
  • Cell Line, Tumor
  • Cell Proliferation
  • Chemistry, Pharmaceutical / methods*
  • Drug Design
  • Drug Screening Assays, Antitumor
  • Enzyme Inhibitors / pharmacology
  • ErbB Receptors / chemistry*
  • Humans
  • Inhibitory Concentration 50
  • Lapatinib
  • Models, Chemical
  • Molecular Conformation
  • Pyrimidines / chemistry*
  • Quinazolines / pharmacology
  • Receptor, ErbB-2 / antagonists & inhibitors*

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Pyrimidines
  • Quinazolines
  • thienopyrimidine
  • Lapatinib
  • ErbB Receptors
  • Receptor, ErbB-2